Samsung Union Talks Enter Final Stage as Strike Threat Looms 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Alibaba Stock Surges After Strong Q4 Earnings Boosted by AI and Cloud Growth 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
WATERTOWN, Mass., Sept. 22, 2016 -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker, the Company’s newly-appointed President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, September 27, 2016 at 1:30 pm. ET. The conference will be held at the Sofitel Hotel in New York City.
The presentation will be webcast at http://wsw.com/webcast/ladenburg2/psdv and a link will also be available at the Company's website.
About pSivida Corp. pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug delivery products primarily for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the United States and three E.U. countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida’s lead product candidate, Medidur™, a micro-insert for posterior uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017. pSivida’s pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.
Contact: EVC Group Michael Polyviou/Doug Sherk – Investors [email protected]; [email protected] 212.850.6020; 415.652.9100
